Diagnosis and quantification of bone marrow fibrosis are significantly biased by the pre-staining processing of bone marrow biopsies

被引:8
作者
Buesche, G [1 ]
Georgii, A [1 ]
Kreipe, HH [1 ]
机构
[1] Hannover Med Sch, Dept Pathol, D-30625 Hannover, Germany
关键词
bone marrow biopsies; bone marrow fibrosis; chronic idiopathic myelofibrosis; chronic myeloid leukaemia; fixation; interlaboratory variation; observer disagreement; paraffin embedding; plastic embedding; quantification;
D O I
10.1111/j.1365-2559.2005.02302.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Aims: Marrow fibrosis (MF) is an unfavourable, often lethal complication of haematological neoplasms. Although biopsy technique and staining procedure are standardized, the prestaining processing of bone marrow biopsies (BMBs) varies markedly without any existing data on its significance for the diagnosis of MF. Methods and results: In this study on 712 BMBs from 296 patients with chronic idiopathic myelofibrosis (CIMF), chronic myeloid leukaemia (CML), or healthy bone marrow, MF was a characteristic complication of CML and CIMF. However, diagnosis and quantification of MF and detection of its prognostic significance were significantly biased by fixation, decalcification, embedding, marrow tissue shrinkage during biopsy processing and the thickness of marrow sections (P < 0.000005). The relevance of these influences was explained by their effect on the marrow volume to which the fibre content was related, whereas the stainability of fibres was not affected. Semiquantitative grading of fibrosis and measurements of fibre density could not be adjusted to various methods of processing of bone marrow biopsies (P < 0.003). Conclusions: Evaluations of MF and its prognostic significance should consider the bias due to the prestaining processing of BMBs and the necessity of an adjustment to the thickness of tissue sections and the degree of marrow tissue shrinkage.
引用
收藏
页码:133 / 148
页数:16
相关论文
共 31 条
[1]  
BAUERMEISTER DE, 1971, AM J CLIN PATHOL, V56, P24
[2]   Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis [J].
Beham-Schmid, C ;
Apfelbeck, U ;
Sill, H ;
Tsybrovsky, O ;
Höfler, G ;
Haas, OA ;
Linkesch, W .
BLOOD, 2002, 99 (01) :381-383
[3]   Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemia [J].
Buesche, G ;
Freund, M ;
Hehlmann, R ;
Georgii, A ;
Ganser, A ;
Hecker, H ;
Heimpel, H ;
Fonatsch, C ;
Heinze, B ;
Pfirrmann, M ;
Holgado, S ;
Schmeil, A ;
Tobler, A ;
Hasford, J ;
Buhr, T ;
Kreipe, HH .
LEUKEMIA, 2004, 18 (09) :1460-1467
[4]   Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trial [J].
Buesche, G ;
Hehlmann, R ;
Hecker, H ;
Heimpel, H ;
Heinze, B ;
Schmeil, A ;
Pfirrmann, M ;
Gomez, G ;
Tobler, A ;
Herrmann, H ;
Kappler, M ;
Hasford, J ;
Buhr, T ;
Kreipe, HH ;
Georgii, A .
LEUKEMIA, 2003, 17 (12) :2444-2453
[5]   Evaluating the volume ratio of bone marrow affected by fibrosis: A parameter crucial for the prognostic significance of marrow fibrosis in chronic myeloid leukemia [J].
Buesche, G ;
Georgii, A ;
Duensing, A ;
Schmeil, A ;
Schlue, J ;
Kreipe, HH .
HUMAN PATHOLOGY, 2003, 34 (04) :391-401
[6]  
Castro-Malaspina H, 1984, Prog Clin Biol Res, V154, P307
[7]  
CERVANTES F, 1989, ACTA HAEMATOL-BASEL, V82, P12
[8]  
FOHLMEISTER I, 1988, ANAL QUANT CYTOL, V10, P110
[9]   The histopathology of chronic myeloproliferative diseases [J].
Georgii, A ;
Buesche, G ;
Kreft, A .
BAILLIERES CLINICAL HAEMATOLOGY, 1998, 11 (04) :721-749
[10]  
Goldstein NS, 1999, AM J CLIN PATHOL, V111, P349